核-壳结构的脂质-聚合物杂化纳米粒的研究进展

刘丹; 张军东; 廉云飞; 房秋雨; 李娟

doi:10.3969/j.issn.1006-0111.2018.01.003

核-壳结构的脂质-聚合物杂化纳米粒的研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.003

1.
中国药科大学药学院, 江苏南京 211198
2.
上海昊海生物科技股份有限公司, 上海 201600

Advances in the studies of core-shell-type lipid-polymer hybrid nanoparticles

1.
School of pharmacy, China Pharmaceutical University, Nanjng 211198, China
2.
Haohai Biotechnology Co. Ltd, Shanghai 201600, China

摘要: 核-壳结构的脂质-聚合物杂化纳米粒（CSLPHNs）是以具有生物可降解性的聚合物纳米粒为核，外层包覆单层或多层具有生物膜仿生性的脂质壳而形成，结合了纳米粒和脂质体的双重优点，具有粒径小、载药量高、生物相容性好及缓控释给药等优势，在药物递送系统中应用甚广。笔者在查阅近年国内外文献的基础上归纳了CSLPHNs的基本特性、制备方法及在眼部给药、肿瘤治疗及临床诊断成像中的最新研究进展。
- 核-壳结构 /
- 脂质-聚合物杂化纳米粒 /
- 药物递送系统 /
- 肿瘤靶向
Abstract: Core-shell-type lipid-polymer hybrid nanoparticles(CSLPHNs) are composed by a biodegradable polymeric core coated with single or multiple layers of biomimetic lipids, which combine the benefits of polymeric nanoparticles and liposomes. CSLPHNs have the advantages of small particle size, high drug loading, good biocompatibility and controlled release capability. It has wide applications as a novel drug delivery system. This review gives a brief introduction in characteristics, preparation methods and applications of CSLPHNs, specifically summarizes the developments in the fields of ophthalmic drug delivery, tumor therapy and medical diagnostic imaging.
- core-shell structure /
- lipid-polymer hybrid nanoparticles /
- drug delivery system /
- tumor targeted

[1]	Mandal B, Bhattacharjee H, Mittal N, et al. Core shell-type lipid polymer hybrid nanoparticles as a drug delivery platform[J]. Nanomedicine, 2013, 9(4):474-491.
[2]	Hadinoto K, Sundaresan A, Cheow WS. Lipid polymer hybrid nanoparticles as a new generation therapeutic delivery platform:a review[J].Eur J Pharm Biopharm, 2013, 85(3Pt A):427-443.
[3]	赵一擎, 刘颖, 冯年平. 脂质聚合物纳米粒的研究进展[J]. 华西药学杂志, 2014, 29(5):602-605.
[4]	王盈. 载溶酶体的脂质-聚合物杂化纳米粒的制备、表征和胶体稳定性评价[J]. 中国医药工业杂志,2016,47(11):1453.
[5]	Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery[J]. Biomaterials, 2009, 30(8):1627-1634.
[6]	杨龙, 陈凌云, 魏刚. 眼用脂质纳米制剂的研究进展[J]. 中国医药工业杂志, 2016, 47(12):1592-1599.
[7]	Zhang L, Zhu D, Dong X, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery[J].Int J Nanomedicine,2015, 10:2101-2114.
[8]	Almeida H, Amaral MH, Lob o P, et al. Applications of poloxamers in ophthalmic pharmaceutical formulations:an overview[J].Expert Opin Drug Deliv, 2013, 10(9):1223-1237.
[9]	Bucolo C, Drago F, Salomone S. Ocular drug delivery:a clue from nanotechnology[J].Front Pharmacol, 2012, 3(3):188.
[10]	蒋敏, 甘莉, 甘勇, 等. 新型眼用脂质载体制剂的研究进展[J]. 中国药学杂志, 2012, 47(16):1265-1270.
[11]	Diebold Y, Jarrín M, Saez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP)[J]. Biomaterials, 2007, 28(8):1553-1564.
[12]	Gan L, Wang J, Zhao Y, et al. Hyaluronan-modified core shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection[J]. Biomaterials, 2013, 34(24):5978-5987.
[13]	Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859):2224-2260.
[14]	Krishnamurthy S, Vaiyapuri R, Zhang L, et al. Lipid-coated polymeric nanoparticles for cancer drug delivery[J].Biomater Sci, 2015, 3(7):923-936.
[15]	Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents.[J]. Adv Drug Deliv Rev, 2002, 54(5):675-693.
[16]	Shen Z, Loe DT, Awino JK, et al. Self-assembly of core-polyethylene glycol-lipid shell (CPLS) nanoparticles and their potential as drug delivery vehicles[J]. Nanoscale, 2016, 8(31):14821-14835.
[17]	Wang F, Chen L, Zhang R, et al. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer[J]. J Control Release, 2014, 196:222-233.
[18]	Shi K, Zhou J, Zhang Q, et al. Arginine-glycine-aspartic acid-modified lipid-polymer hybrid nanoparticles for docetaxel delivery in glioblastoma multiforme[J]. J Biomed Nanotechnol, 2015, 11(3):382-391.
[19]	Zhao Y, Lin D, Wu F, et al. Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery[J]. Int J Mol Sci, 2014, 15(10):17565-17576.
[20]	张悦, 邢仕歌, 王震, 等. 核酸适配体在靶向药物传递中的研究进展[J]. 生物化学与生物物理进展, 2015, 42(3):236-243.
[21]	Li L, Xiang D, Shigdar S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells[J]. Int J Nanomedicine, 2014, 9:1083-1096.
[22]	Zhang LJ, Wu B, Zhou W, et al. Two-component reduction-sensitive lipid polymer hybrid nanoparticles for triggered drug release and enhanced in vitro and in vivo anti-tumor efficacy[J]. Biomater Sci, 2016, 5(1):98-110.
[23]	Kong SD, Sartor M, Hu CM, et al. Magnetic field activated lipid polymer hybrid nanoparticles for stimuli-responsive drug release[J]. Acta Biomater, 2013, 9(3):5447-5452.
[24]	Clawson C, Ton L, Aryal S, et al. Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly (ethylene glycol) shedding[J]. Langmuir, 2011, 27(17):10556-10561.
[25]	Yan J, Wang Y, Zhang X, et al. Targeted nanomedicine for prostate cancer therapy:docetaxel and curcumin co-encapsulated lipid polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo[J]. Drug Deliv, 2016, 23(5):1757-1762.
[26]	Zhao X, Li F, Li Y, et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer[J]. Biomaterials, 2015, 46:13-25.
[27]	Mieszawska AJ, Gianella A, Cormode DP, et al. Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging[J]. Chem Commun(Camb), 2012, 48(47):5835-5837.

[1]	姜建芳, 王思平, 何新军. 硝苯地平在高血压孕妇中的药物毒性：基于FARES数据库的真实世界研究 . 药学实践与服务, 2025, 43(6): 307-312. doi: 10.12206/j.issn.2097-2024.202501001
[2]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2025, 43(1): 26-29, 40. doi: 10.12206/j.issn.2097-2024.202404034
[3]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[4]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2025, 43(3): 136-142, 150. doi: 10.12206/j.issn.2097-2024.202310043
[5]	王彦, 康乐, 陈文, 方琦, 俞仲望, 曹莉. 基于CiteSpace结合系统评价方法分析药品不良反应自动监测系统的热点及优势 . 药学实践与服务, 2025, 43(): 1-8. doi: 10.12206/j.issn.2097-2024.202501034
[6]	白云俊, 赵玉洋, 金艳, 付璐, 袁媛. 蓝草类药材基原植物叶片表皮显微结构研究 . 药学实践与服务, 2025, 43(4): 174-179. doi: 10.12206/j.issn.2097-2024.202404069
[7]	吴若南, 汤文敏, 高林, 吴岳林, 罗川, 缪震元. RRx-001衍生物的合成和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408053
[8]	魏莱, 董国强, 盛春泉. 靶向SARS-CoV-2主蛋白酶的PROTAC设计、合成与蛋白降解活性研究 . 药学实践与服务, 2025, 43(5): 235-241, 258. doi: 10.12206/j.issn.2097-2024.202503063
[9]	柯刚, 董清科, 肖世容, 龚茜, 李荣, 汪代杰. 基于网络药理学探讨参苓白术散治疗肿瘤恶病质的作用机制 . 药学实践与服务, 2025, 43(5): 242-250. doi: 10.12206/j.issn.2097-2024.202208115
[10]	周娇, 郑建雨, 王思真, 杨峰. mRNA肿瘤疫苗非病毒递送系统研究进展 . 药学实践与服务, 2025, 43(3): 109-116. doi: 10.12206/j.issn.2097-2024.202410034
[11]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[12]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[13]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[14]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[15]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[16]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[17]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[18]	邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴. 虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
[19]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[20]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034

点击查看大图

计量

文章访问数: 5391
HTML全文浏览量: 578
PDF下载量: 588
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

核-壳结构的脂质-聚合物杂化纳米粒的研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.003

Advances in the studies of core-shell-type lipid-polymer hybrid nanoparticles

计量

核-壳结构的脂质-聚合物杂化纳米粒的研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.003

1. 中国药科大学药学院, 江苏南京 211198

2. 上海昊海生物科技股份有限公司, 上海 201600

English Abstract

Advances in the studies of core-shell-type lipid-polymer hybrid nanoparticles

1. School of pharmacy, China Pharmaceutical University, Nanjng 211198, China

2. Haohai Biotechnology Co. Ltd, Shanghai 201600, China

全文HTML

目录

留言板

核-壳结构的脂质-聚合物杂化纳米粒的研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.003

Advances in the studies of core-shell-type lipid-polymer hybrid nanoparticles

计量

出版历程

核-壳结构的脂质-聚合物杂化纳米粒的研究进展

doi: 10.3969/j.issn.1006-0111.2018.01.003

1. 中国药科大学药学院, 江苏 南京 211198 2. 上海昊海生物科技股份有限公司, 上海 201600

English Abstract

Advances in the studies of core-shell-type lipid-polymer hybrid nanoparticles

1. School of pharmacy, China Pharmaceutical University, Nanjng 211198, China 2. Haohai Biotechnology Co. Ltd, Shanghai 201600, China

全文HTML

目录

1. 中国药科大学药学院, 江苏南京 211198

2. 上海昊海生物科技股份有限公司, 上海 201600

1. School of pharmacy, China Pharmaceutical University, Nanjng 211198, China

2. Haohai Biotechnology Co. Ltd, Shanghai 201600, China